Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Airstrike
Donald Trump
War
World Cup
Social Media
Real Madrid
Cricket
Soccer
Military
Manchester United
Cryptocurrency
Artificial Intelligence
Epidermolysis Bullosa News image

News from Epidermolysis Bullosa News

We’ve assigned a media bias rating of unknown to Epidermolysis Bullosa News. You can read more about our methodology here.

Information about Epidermolysis Bullosa News

Where is Epidermolysis Bullosa News located?Epidermolysis Bullosa News's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Epidermolysis Bullosa News News

Dupilumab treatment eases disease severity, itching in DEB: Study
Germany · Germany

Dupilumab treatment eases disease severity, itching in DEB: Study

Treatment with dupilumab, a medicine approved for certain inflammatory disorders, eases itch and disease severity in people with different subtypes of dystrophic epidermolysis bullosa (DEB), a small study suggests. Dupilumab-related benefits seen in a woman before she stopped treatment and got pregnant were mostly maintained throughout her pregnancy and childbirth. Treatment had no impact on conception or on the woman’s health or her infant’s, a…Read Article
Study: Long-term Vyjuvek in dystrophic epidermolysis bullosa safe...
United States · United States

Study: Long-term Vyjuvek in dystrophic epidermolysis bullosa safe...

Long-term treatment with the topical gene therapy Vyjuvek (beremagene geperpavec) was associated with continued wound closure and high patient satisfaction among people with dystrophic epidermolysis bullosa (DEB) who took part in an open-label extension (OLE) study. The therapy was also well tolerated over up to more than two years of treatment. “Overall, the benefit-risk profile of [Vyjuvek] supports the continued long-term treatment of childre…Read Article

Blisters from adhesive dressings complicated my postpartum days

At 20, I welcomed my first child via cesarean section, a moment of joy that came with unexpected challenges because of my mild case of epidermolysis bullosa (EB). While my skin is sensitive and blisters easily, my EB is manageable compared with many others with the condition. Still, the adhesive wound dressings applied after my surgery turned a routine procedure into a painful lesson about living with a rare disease as a young mother. I had my f…Read Article

Increasing the Efficiency of Homology-Directed Repair for CRISPR-Cas9-Induced Precise Gene Editing in Mammalian Cells

67% Center coverage: 3 sources
The efficiency of precise CRISPR/Cas9 genome editing is increased by inhibition of the nonhomologous end joining pathway. The insertion of precise genetic modifications by genome editing tools such as CRISPR-Cas9 is limited by the relatively low efficiency of homology-directed repair (HDR) compared with the higher efficiency of the nonhomologous end-joining (NHEJ) pathway. To enhance HDR, enabling the insertion of precise genetic modifications, …DNASee the Story

Lurie Children’s Becomes First Treatment Center for Zevaskyn Gene Therapy in Patients with RDEB

ZEVASKYN, the first FDA-approved gene therapy for wounds in recessive dystrophic epidermolysis bullosa, is now available at Lurie Children's Hospital.Chicago, IL · ChicagoSee the Story

Paradigm to seek FDA approval for epidermolysis bullosa treatment

Paradigm Therapeutics is planning to seek U.S. Food and Drug Administration (FDA) approval for the experimental cream SD-101 to treat all forms of epidermolysis bullosa (EB). Paradigm said it plans to submit a new drug application in the latter part of this year. If SD-101 ultimately is approved, Paradigm plans to sell it under the name Zorblisa. “We are excited about the opportunity to complete the development activities for SD-101 (Zorblisa) a…United States · United StatesRead Article

What my realistic self-care plan looks like in a busy season of life

The organization where I work is governed by a model that asks each employee to have a self-care plan. Each month, our supervisor is supposed to ask if we’ve been using it and what they can do to help ensure we do so. Honestly, I don’t even know what’s on my self-care plan anymore. I read a few pages of a book before bed, and I’m always listening to an additional book on Audible. I watch videos of those guys who harmonize in their kitchen with c…North Carolina · North CarolinaRead Article

Gene therapy Vyjuvek wins approval in Europe for DEB patients from...

The European Commission has approved the topical gene therapy Vyjuvek (beremagene geperpavec) to treat wounds, starting at birth in people with dystrophic epidermolysis bullosa (DEB) who have disease-causing mutations in the COL7A1 gene. The decision, which applies to all European Union countries, and includes Iceland, Norway, and Liechtenstein, makes Vyjuvek the first corrective medicine that’s designed to address the disease’s root genetic cau…Mississippi · MississippiRead Article

FDA Approves Zevaskyn for Rare, Genetic Skin Disorder

44% Center coverage: 29 sources
FDA · United StatesSee the Story

Jessie Anna Ward Kelley

Jessie Anna Ward Kelley News Staff Thu, 04/10/2025 - 14:43 In-page image(s) X Body Celebration of Life services for Jessie Anna Ward Kelley, 80, of Mabank were held April 9, 2025, at Eubank Cedar Creek Memorial Park in Mabank with Bro. Donald Kile officiating.Jessie passed from this life March 28, 2025, surrounded by her loving family. She was born Sept. 14, 1944, in Washington D.C., to Jesse Clifford and Hazel Annie (Taylor) Ward. Growing up…West Virginia · West VirginiaSee the Story

Breaking News Topics Related to Epidermolysis Bullosa News

United States icon

United States

News
For You
SearchBlindspotLocal